Drug Approvals in Malaysia

23 April 1995

Registration applications for 1,377 pharmaceutical products were processed by Malaysia's Drug Control Authority in 1994. Of these, 635 were approved, 569 were rejected, 149 applications were cancelled and 24 were deferred, according to the DCA's newsletter.

The DCA also notes that 37 products were recalled during 1994 for failing to meet quality and safety requirements, and that seven pharmaceutical factories were penalized and their manufacturing licenses temporarily suspended, for non-compliance with Good Manufacturing Practice requirements.

With the beginning of 1995, 10 years have passed since the DCA was established under Malaysia's Control of Drugs and Cosmetics Regulations 1984, reports the newsletter. Looking at what has been achieved over this period, it notes that implementation of the Regulations, which began in 1985, is well on schedule, with the first and second phases of the implementation schedule, covering prescription and over-the-counter products, having been completed. To date, the DCA says it has approved 6,349 prescription drug products, 3,968 OTC medicines and 148 hair-dye products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight